RTEL1의 발현을 조절하기 위한 올리고뉴클레오티드
본원 발명은 HBV 감염, 특히 만성 HBV 감염의 치료에서 이용을 위한 RTEL1 저해제에 관계한다. 본원 발명은 특히, cccDNA, 예컨대 HBV cccDNA를 불안정화하기 위한 RTEL1 저해제의 용도에 관계한다. 본원 발명은 또한, RTEL1에 상보적이고 RTEL1 mRNA를 감소시킬 수 있는 안티센스 올리고뉴클레오티드에 관계한다. 제약학적 조성물 및 HBV 감염의 치료 및/또는 예방에서 이의 용도 역시 본원 발명 내에 포함된다. The present invention relates to a RTEL1 inhibitor f...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | kor |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | WALLIER ANGELINA TROPBERGER PHILIPP BERRERA MARCO KAMMLER SUSANNE LEONARD BRIAN FELBER JOSEPHINE TRIYATNI MIRIAM KAM THONG TONY HOFLACK JEAN CHRISTOPHE ZHANG JITAO DAVID PEDERSEN LYKKE TURLEY DANIEL JEREMY |
| description | 본원 발명은 HBV 감염, 특히 만성 HBV 감염의 치료에서 이용을 위한 RTEL1 저해제에 관계한다. 본원 발명은 특히, cccDNA, 예컨대 HBV cccDNA를 불안정화하기 위한 RTEL1 저해제의 용도에 관계한다. 본원 발명은 또한, RTEL1에 상보적이고 RTEL1 mRNA를 감소시킬 수 있는 안티센스 올리고뉴클레오티드에 관계한다. 제약학적 조성물 및 HBV 감염의 치료 및/또는 예방에서 이의 용도 역시 본원 발명 내에 포함된다.
The present invention relates to a RTEL1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of RTEL1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to antisense oligonucleotides which are complementary to RTEL1 and capable of reducing a RTEL1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_KR20210033004A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>KR20210033004A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_KR20210033004A3</originalsourceid><addsrcrecordid>eNrjZHAKCnH1MXwzd4bC6w1z3s5oeTO3ReHNwg1vFnS8nTrj1Y4NCm_mtLydOkfhzYw1r5etebV5wevOLW8bt7xe0PFmxpK33RteT57Dw8CalphTnMoLpbkZlN1cQ5w9dFML8uNTiwsSk1PzUkvivYOMDIwMDQyMjQ0MTByNiVMFAGuSRJE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>RTEL1의 발현을 조절하기 위한 올리고뉴클레오티드</title><source>esp@cenet</source><creator>WALLIER ANGELINA ; TROPBERGER PHILIPP ; BERRERA MARCO ; KAMMLER SUSANNE ; LEONARD BRIAN ; FELBER JOSEPHINE ; TRIYATNI MIRIAM ; KAM THONG TONY ; HOFLACK JEAN CHRISTOPHE ; ZHANG JITAO DAVID ; PEDERSEN LYKKE ; TURLEY DANIEL JEREMY</creator><creatorcontrib>WALLIER ANGELINA ; TROPBERGER PHILIPP ; BERRERA MARCO ; KAMMLER SUSANNE ; LEONARD BRIAN ; FELBER JOSEPHINE ; TRIYATNI MIRIAM ; KAM THONG TONY ; HOFLACK JEAN CHRISTOPHE ; ZHANG JITAO DAVID ; PEDERSEN LYKKE ; TURLEY DANIEL JEREMY</creatorcontrib><description>본원 발명은 HBV 감염, 특히 만성 HBV 감염의 치료에서 이용을 위한 RTEL1 저해제에 관계한다. 본원 발명은 특히, cccDNA, 예컨대 HBV cccDNA를 불안정화하기 위한 RTEL1 저해제의 용도에 관계한다. 본원 발명은 또한, RTEL1에 상보적이고 RTEL1 mRNA를 감소시킬 수 있는 안티센스 올리고뉴클레오티드에 관계한다. 제약학적 조성물 및 HBV 감염의 치료 및/또는 예방에서 이의 용도 역시 본원 발명 내에 포함된다.
The present invention relates to a RTEL1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of RTEL1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to antisense oligonucleotides which are complementary to RTEL1 and capable of reducing a RTEL1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.</description><language>kor</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210325&DB=EPODOC&CC=KR&NR=20210033004A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210325&DB=EPODOC&CC=KR&NR=20210033004A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>WALLIER ANGELINA</creatorcontrib><creatorcontrib>TROPBERGER PHILIPP</creatorcontrib><creatorcontrib>BERRERA MARCO</creatorcontrib><creatorcontrib>KAMMLER SUSANNE</creatorcontrib><creatorcontrib>LEONARD BRIAN</creatorcontrib><creatorcontrib>FELBER JOSEPHINE</creatorcontrib><creatorcontrib>TRIYATNI MIRIAM</creatorcontrib><creatorcontrib>KAM THONG TONY</creatorcontrib><creatorcontrib>HOFLACK JEAN CHRISTOPHE</creatorcontrib><creatorcontrib>ZHANG JITAO DAVID</creatorcontrib><creatorcontrib>PEDERSEN LYKKE</creatorcontrib><creatorcontrib>TURLEY DANIEL JEREMY</creatorcontrib><title>RTEL1의 발현을 조절하기 위한 올리고뉴클레오티드</title><description>본원 발명은 HBV 감염, 특히 만성 HBV 감염의 치료에서 이용을 위한 RTEL1 저해제에 관계한다. 본원 발명은 특히, cccDNA, 예컨대 HBV cccDNA를 불안정화하기 위한 RTEL1 저해제의 용도에 관계한다. 본원 발명은 또한, RTEL1에 상보적이고 RTEL1 mRNA를 감소시킬 수 있는 안티센스 올리고뉴클레오티드에 관계한다. 제약학적 조성물 및 HBV 감염의 치료 및/또는 예방에서 이의 용도 역시 본원 발명 내에 포함된다.
The present invention relates to a RTEL1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of RTEL1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to antisense oligonucleotides which are complementary to RTEL1 and capable of reducing a RTEL1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHAKCnH1MXwzd4bC6w1z3s5oeTO3ReHNwg1vFnS8nTrj1Y4NCm_mtLydOkfhzYw1r5etebV5wevOLW8bt7xe0PFmxpK33RteT57Dw8CalphTnMoLpbkZlN1cQ5w9dFML8uNTiwsSk1PzUkvivYOMDIwMDQyMjQ0MTByNiVMFAGuSRJE</recordid><startdate>20210325</startdate><enddate>20210325</enddate><creator>WALLIER ANGELINA</creator><creator>TROPBERGER PHILIPP</creator><creator>BERRERA MARCO</creator><creator>KAMMLER SUSANNE</creator><creator>LEONARD BRIAN</creator><creator>FELBER JOSEPHINE</creator><creator>TRIYATNI MIRIAM</creator><creator>KAM THONG TONY</creator><creator>HOFLACK JEAN CHRISTOPHE</creator><creator>ZHANG JITAO DAVID</creator><creator>PEDERSEN LYKKE</creator><creator>TURLEY DANIEL JEREMY</creator><scope>EVB</scope></search><sort><creationdate>20210325</creationdate><title>RTEL1의 발현을 조절하기 위한 올리고뉴클레오티드</title><author>WALLIER ANGELINA ; TROPBERGER PHILIPP ; BERRERA MARCO ; KAMMLER SUSANNE ; LEONARD BRIAN ; FELBER JOSEPHINE ; TRIYATNI MIRIAM ; KAM THONG TONY ; HOFLACK JEAN CHRISTOPHE ; ZHANG JITAO DAVID ; PEDERSEN LYKKE ; TURLEY DANIEL JEREMY</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_KR20210033004A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>kor</language><creationdate>2021</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>WALLIER ANGELINA</creatorcontrib><creatorcontrib>TROPBERGER PHILIPP</creatorcontrib><creatorcontrib>BERRERA MARCO</creatorcontrib><creatorcontrib>KAMMLER SUSANNE</creatorcontrib><creatorcontrib>LEONARD BRIAN</creatorcontrib><creatorcontrib>FELBER JOSEPHINE</creatorcontrib><creatorcontrib>TRIYATNI MIRIAM</creatorcontrib><creatorcontrib>KAM THONG TONY</creatorcontrib><creatorcontrib>HOFLACK JEAN CHRISTOPHE</creatorcontrib><creatorcontrib>ZHANG JITAO DAVID</creatorcontrib><creatorcontrib>PEDERSEN LYKKE</creatorcontrib><creatorcontrib>TURLEY DANIEL JEREMY</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>WALLIER ANGELINA</au><au>TROPBERGER PHILIPP</au><au>BERRERA MARCO</au><au>KAMMLER SUSANNE</au><au>LEONARD BRIAN</au><au>FELBER JOSEPHINE</au><au>TRIYATNI MIRIAM</au><au>KAM THONG TONY</au><au>HOFLACK JEAN CHRISTOPHE</au><au>ZHANG JITAO DAVID</au><au>PEDERSEN LYKKE</au><au>TURLEY DANIEL JEREMY</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>RTEL1의 발현을 조절하기 위한 올리고뉴클레오티드</title><date>2021-03-25</date><risdate>2021</risdate><abstract>본원 발명은 HBV 감염, 특히 만성 HBV 감염의 치료에서 이용을 위한 RTEL1 저해제에 관계한다. 본원 발명은 특히, cccDNA, 예컨대 HBV cccDNA를 불안정화하기 위한 RTEL1 저해제의 용도에 관계한다. 본원 발명은 또한, RTEL1에 상보적이고 RTEL1 mRNA를 감소시킬 수 있는 안티센스 올리고뉴클레오티드에 관계한다. 제약학적 조성물 및 HBV 감염의 치료 및/또는 예방에서 이의 용도 역시 본원 발명 내에 포함된다.
The present invention relates to a RTEL1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of RTEL1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to antisense oligonucleotides which are complementary to RTEL1 and capable of reducing a RTEL1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | kor |
| recordid | cdi_epo_espacenet_KR20210033004A |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | RTEL1의 발현을 조절하기 위한 올리고뉴클레오티드 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T19%3A54%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=WALLIER%20ANGELINA&rft.date=2021-03-25&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EKR20210033004A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |